Topic: The Lancet
The selective vitamin D receptor activator paricalcitol can reduce albuminuria in patients with type 2 diabetes already being treated with renin-angiotensin-aldosterone system inhibitors, according to research published online Nov. 4 in The Lancet.. The primary end point was the percentage change in ...
Intensive control of blood glucose levels does not reduce the odds of cardiovascular disease for those with long-term type 2 diabetes who are at risk of heart problems, as researchers have known. The study results, published online June 29 in The Lancet, ...
In patients with established type 2 diabetes, intensive glucose-lowering therapy improves some outcomes but is also associated with increased mortality, weight gain, and an increased risk of severe hypoglycemia, according to a study published online June 29 in The Lancet to coincide ...
Intensive control of blood glucose levels does not reduce the odds of cardiovascular disease for those with long-term type 2 diabetes who are at risk of heart problems, as researchers have known. The study results, published online June 29 in The Lancet, ...
In patients with type 2 diabetes who have inadequate glycemic control despite treatment with maximum tolerated doses of first-line blood-glucose lowering drugs for three months or longer, a once-weekly injection of exenatide may be associated with better glycemic control and greater weight ...
In the United States, initiation of screening for type 2 diabetes between ages 30 and 45, with repeat screenings every three to five years, is cost effective, according to a study published online March 30 in The Lancet.. Richard Kahn, Ph.D., of ...
An experimental diabetes drug called liraglutide appears to outperform exenatide (Byetta), the only currently approved drug in its class, a study funded by liraglutide's maker, Novo Nordisk, shows.. In the new phase III trial -- usually the last kind done before marketing ...
Childhood type 1 diabetes cases are on the rise in Europe, and are set to double among the under-fives by 2020 compared to 2005, according to a study published online on May 28 in The Lancet.. Christopher C. Patterson, Ph.D., of Queen's ...
Because women with gestational diabetes are at increased risk of subsequently developing type 2 diabetes, increasing awareness among both physicians and patients about the risk can be used as an opportunity to promote behavior that may delay or prevent the disease, according ...
In patients with type 2 diabetes, fenofibrate may lower the risk of minor amputation, according to a study published in the May 23 issue of The Lancet.. Compared to controls, the researchers found that the fenofibrate group had a lower risk of ...
